A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting now · Phase 1
Conditions studied: Solid Tumors
In brief
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Key facts
- Study ID
- NCT07123103
- Run by
- Exelixis
- People needed
- 150
- Starts
- 2025-08-18
- Expected to finish
- 2028-02-01
- Last updated by the study team
- 2026-02-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Exelixis Clinical Site #5 — Rogers, Arkansas, United States (enrolling)
- Exelixis Clinical Site #9 — Los Angeles, California, United States (enrolling)
- Exelixis Clinical Site #6 — Washington D.C., District of Columbia, United States (enrolling)
- Exelixis Clinical Site #4 — Orlando, Florida, United States (enrolling)
- Exelixis Clinical Site #3 — Grand Rapids, Michigan, United States (enrolling)
- Exelixis Clinical Site #7 — New Brunswick, New Jersey, United States (enrolling)
- Exelixis Clinical Site #2 — Huntersville, North Carolina, United States (enrolling)
- Exelixis Clinical Site #8 — Houston, Texas, United States (enrolling)
- Exelixis Clinical Site #1 — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.